Gold bars to be exempt from tariffs, White House clarifies
On Monday, H.C. Wainwright analysts assumed coverage of Senseonics Holdings stock, assigning a Buy rating to the company. The research firm set a price target of $1.10 for the biotechnology company, which is listed on the New York Stock Exchange under the ticker (NYSE:SENS). According to InvestingPro data, the stock currently trades at $0.52, with two analysts recently revising their earnings estimates upward for the upcoming period.
Senseonics Holdings, a commercial-stage biotechnology company with a market capitalization of $423 million, focuses on developing and commercializing continuous glucose monitoring (CGM) systems. The company is noted for having the only 365-day continuous glucose monitoring system available in the market. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 6.88, though it operates with moderate debt levels.
The analysts from H.C. Wainwright highlighted the unique position of Senseonics in the market, emphasizing its innovative approach to diabetes management. This coverage initiation reflects a positive outlook on the company’s potential within the healthcare sector.
The price target of $1.10 reflects the analysts’ expectations for the stock’s performance, providing a specific valuation goal for investors interested in the biotechnology firm’s offerings.
In other recent news, Senseonics Holdings, Inc. reported its Q1 2025 earnings with mixed results. The company’s earnings per share (EPS) exceeded expectations, coming in at -$0.02 compared to the forecasted -$0.03. However, revenue fell short, reaching $6.3 million against a projected $6.92 million. Senseonics also announced a public stock offering and a private placement agreement with Abbott Laboratories (NYSE:ABT), which plans to purchase up to $25 million of Senseonics’ common stock. This move is contingent upon the closure of the public offering, with proceeds intended for product development and general corporate purposes.
Additionally, Senseonics launched the Eversense 365 continuous glucose monitor, marking a significant step in their product lineup. The company reduced its debt to $35.3 million, strengthening its balance sheet. Analyst firms TD Cowen and Barclays (LON:BARC) are involved in the stock offering as joint book-running managers. The company remains focused on expanding its global patient base and plans to launch its products in the European market later in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.